Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Newbury Pharmaceuticals AB's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:P52's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.39 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Newbury Pharmaceuticals AB (FRA:P52) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Newbury Pharmaceuticals AB 5-Year Yield-on-Cost % Related Terms
FRA:P52 vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's 5-Year Yield-on-Cost % falls into.
Newbury Pharmaceuticals AB 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Newbury Pharmaceuticals AB (FRA:P52) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Newbury Pharmaceuticals AB and its competitors. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Newbury Pharmaceuticals AB's 5-Year Yield-on-Cost % too high?
Newbury Pharmaceuticals AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 507 companies for 5-Year Yield-on-Cost %. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.39, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.
Key valuation signals for FRA:P52:
5-Year Yield-on-Cost %: 0.00
GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for FRA:P52
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P52 has been successfully added to your 
